Core Viewpoint - Silver诺医药-B (02591) has seen a stock price increase of over 5%, marking three consecutive days of gains, currently trading at 43.42 HKD with a transaction volume of 7.6433 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B has risen by 5.03% [1] - The current trading price is 43.42 HKD [1] - The trading volume reached 7.6433 million HKD [1] Group 2: Index Inclusion - Silver诺医药 has been included in the Hang Seng Composite Index, with changes effective from December 8, 2025 [1] - This inclusion is part of the quarterly review results of the Hang Seng Index series [1] Group 3: Company Overview - Silver诺医药 is focused on the field of metabolic diseases [1] - The company has multiple innovative drug development pipelines targeting diabetes, obesity, and non-alcoholic fatty liver disease, all of which are self-developed [1] - The company holds global intellectual property rights and has a comprehensive global research and market layout [1]
港股异动 | 银诺医药-B(02591)再涨超5% 下周一正式进入恒生综指 机构称其符合港股通纳入范围